GET DAILY SIGNALSOvid Therapeutics (OVID): $6.00 Analyst Target Suggests +114% Upside from Current Levels
Key Takeaways
- The central $6.00 target is the arithmetic mean of 11 verified analyst price targets reviewed for Ovid Therapeutics Inc. (OVID), a clinical-stage biopharmaceutical company, rounded from a raw average of about $6.05.
- The latest verified market price is about $2.80, meaning the stock would need to rise roughly 114% to reach the $6.00 target.
- Individual analyst price targets range widely, from a low of $4.00 (LifeSci Capital) to a high of $9.00 (Oppenheimer), reflecting very different views on pipeline risk.
- Supporting factors center on two clinical programs: OV329 for epilepsy and OV4071, a first-in-class oral KCC2 activator for psychosis and schizophrenia.
- The biggest risks are binary clinical trial outcomes, heavy cash burn with minimal revenue, and the possibility of equity dilution.
- The average analyst price target is not a forecast or guarantee; it reflects a research horizon and is highly sensitive to upcoming data readouts.
- Readers can explore Major News, Today's Price Move, the Forecast, and Earnings pages for additional detail on this ticker.
- For broader market scanning, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Ovid Therapeutics draws coverage from a modest but generally constructive group of sell-side analysts. Collecting the 11 targets that can be tied to specific firms and analysts shows a spread from roughly $4.00 to $9.00. Their arithmetic mean comes in near $6.05, which rounds cleanly to the $6.00 central target I am using here.
The wide dispersion is typical for a pre-revenue biotech where valuation hinges on clinical outcomes. LifeSci Capital sits at the low end with $4.00, while H.C. Wainwright and B. Riley both use $5.00. Cantor Fitzgerald started at $6.00, Wedbush and Guggenheim are at $7.00, Roth Capital is at $8.00, and Oppenheimer carries the high mark of $9.00. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock’s recent behavior aligns with these views.
Recent moves have been constructive, with several firms lifting targets in 2026. The spread largely comes down to how much credit analysts assign to the more speculative OV4071 program.
Current Market Position and Path Toward the Target
OVID currently trades near $2.80, giving the company a market capitalization around $530 million. Its 52-week range runs from $1.18 to $3.105. Closing the gap to $6.00 would require a move of roughly 114%, a substantial advance that would more than double the share price.
This path rests almost entirely on clinical progress rather than current financial results. The company posted a third-quarter 2026 net loss of about $20.8 million, or $0.10 per share, with essentially no product revenue. Cash, cash equivalents, and marketable securities totaled roughly $161.4 million at the end of September 2026, which management believes will support key studies well into the future.
What Could Support a Move Toward the Target
The bull case centers on two development programs. OV329 is a next-generation GABA-AT inhibitor aimed at drug-resistant epilepsy. It seeks to preserve the efficacy of vigabatrin while sidestepping its known ocular toxicity. Phase 1 data showed no eye-related findings, and the company is now running a photosensitivity proof-of-concept study along with a Phase 2 focal epilepsy trial. OV4071 is an oral, first-in-class direct activator of KCC2, a mechanism the industry has chased for two decades, and it is being positioned for schizophrenia, psychosis, and other neuropsychiatric indications.
Some analysts have noted that success in Parkinson’s disease psychosis alone could add several dollars per share. Positive data in 2027, a clean safety profile so far, and a cash runway extending toward 2029 all underpin the higher targets.
What Could Prevent the Target From Being Reached
The main hurdle remains binary clinical risk. Disappointing results from the OV329 Phase 2 trial or the OV4071 translational study could sharply reduce the pipeline’s perceived value and lead to target cuts. With minimal revenue, the company relies on its cash balance and may need future equity raises; a $250 million mixed securities shelf was filed recently, underscoring dilution risk. Valuation is driven by sentiment around data readouts still months away rather than near-term earnings.
Technical Levels and Market Structure
Over the past 52 weeks, OVID has moved between roughly $1.18 and $3.10 after gaining more than 100% in the prior year. The $3.00–$3.10 zone represents prior resistance, while $2.60–$2.65 has provided short-term support. A sustained break above the 52-week high near $3.10 would be noteworthy technically, yet the $6.00 target lies well beyond any established price level.
Time Horizon and What Investors Should Monitor
Analyst targets generally reflect a roughly 12-month horizon, though the relevant window here stretches into 2027 given the clinical schedule. Key events include the OV329 photosensitivity proof-of-concept readout expected in the first quarter of 2027, the OV4071 translational biomarker readout also targeted for early 2027, the start of a tuberous sclerosis complex study, and OV329 Phase 2 data anticipated in the second half of 2027. Revisions around these milestones, quarterly cash updates, and any financing activity will be the signals to watch most closely.
Using Tickeron’s AI Daily Buy/Sell Signals in Practice
In my own workflow I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. For a volatile, news-driven stock such as OVID, these signals can help surface opportunities and track trend changes more efficiently than manual review alone, adding a useful automated layer to the research process.
Final Assessment
The $6.00 central target represents the average of 11 analyst price targets that range from $4.00 to $9.00, pointing to a roughly 114% move from the current price near $2.80. The wide spread reflects real differences of opinion on the pipeline, especially the more speculative OV4071 asset. Support comes from differentiated mechanisms, an encouraging safety profile to date, and a cash runway into 2029, while the primary risks involve binary clinical outcomes, minimal revenue, and potential dilution. Whether OVID reaches $6.00 will hinge on data readouts across 2027 rather than near-term financials, and no outcome is assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OVID's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OVID turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 48 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology
Advertisement